Alnylam Pharmaceuticals (ALNY) Other Accumulated Expenses (2013 - 2018)

Alnylam Pharmaceuticals' Other Accumulated Expenses history runs 6 years deep, the most recent figure standing at $23.6 million for Q4 2018.

• Quarterly Other Accumulated Expenses rose 117.66% year-over-year to $23.6 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $23.6 million (up 117.66% YoY) and the FY2018 annual result came in at $23.6 million, up 117.66% from the prior year.
• Other Accumulated Expenses was $23.6 million for Q4 2018 at Alnylam Pharmaceuticals, up from $10.9 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $25.4 million in Q1 2014 and bottomed at $3.8 million in Q4 2014.
• A 5-year average of $13.5 million and a median of $11.7 million in 2016 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2016 — Other Accumulated Expenses jumped 154.34% — and 2017, when it slipped 14.02%.
• Alnylam Pharmaceuticals' Other Accumulated Expenses stood at $3.8 million in 2014, then soared by 30.38% to $5.0 million in 2015, then jumped by 154.34% to $12.6 million in 2016, then declined by 14.02% to $10.9 million in 2017, then soared by 117.66% to $23.6 million in 2018.
• Business Quant data shows ALNY's Other Accumulated Expenses at $23.6 million in Q4 2018, $10.9 million in Q4 2017, and $12.6 million in Q4 2016.